Kapitalradar

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r10data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced
Latest available record · 8 Oct 2026

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

Published by 14 Jun 2026
Drag the red line through time · ← → a day · Shift+← → a week. Later days aren’t drawn: they haven’t been published yet.
1733not yet publishedAug 25Sep 25Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26

Scope · likely financings by canton

51 likely financings · 16 May 2026 – 14 Jun 2026 · the feed below shows one weekBS ✕ show all cantonsMap: Natural Earth

Likely financing
Looks like new money from outside investors: Claude, reading the entry and the rule signals, scores it 0.60 or higher.
Undecided
Some financing signals, not enough to call it: a score from 0.35 to below 0.60, or no usable score.
Capital increased
No sign of a financing round: the pre-filter found nothing to send to Claude, or Claude scored it below 0.35. Typical causes are converted loans, assets contributed in kind, reserves turned into capital or a conversion to an AG.
Confirmed round
A financing announcement on startupticker.ch names the company and matches this increase.

Published 8–14 Jun 2026 · canton BS

4 capital increases · 2 shown
Showing: likely financings and confirmed rounds ▾
Show
Capital increases published 8–14 Jun 2026
CompanyStatusNominal share capital (CHF)
before → after		New shares, % of
post-step shares		Announced roundnot disclosed in the SHABSHAB publishedSource
OptimalPSI AGBS · Der Geschäftszweck der Gesellschaft besteht in der Entwicklung und Bereitstellung umfassender Lösungen, …SHAB publication HR02-1006674019Likely financingscore 0.75100’000 → 123’750New shares 19.2%19.2%—11 Jun 2026SHAB publication HR02-1006674019
Nuclidium AGBS · Die Gesellschaft bezweckt die Entwicklung, Herstellung, und den Verkauf von medizinischen einschliesslich …SHAB publication HR02-1006674016Confirmed round · missed by classifierscore 0.15Announced round: CHF 105’000’000 ↗353’812.40 → 402’403.90New shares 12.1%12.1%CHF 105’000’000 ↗11 Jun 2026SHAB publication HR02-1006674016

2 other capital increases published this week ▸